The Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s Lag-3 drug called relatlimab, a checkpoint inhibitor, to treat certain patients with melanoma or metastatic melanoma. The drug was found effective when given with nivolumab (Opdivo), a PD-1 inhibitor also developed by Bristol.